share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4:持股變動聲明-股東 Cormorant Asset Management, LP
美股SEC公告 ·  05/08 17:03

Moomoo AI 已提取核心訊息

Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP已於2024年5月6日完成了對EyePoint Pharmicals, Inc.(埃及)股份的收購。這些交易在公開市場上執行,共收購了85萬股股票。第一筆交易涉及以每股11.70美元的價格購買642,847股股票,而第二筆交易以每股12.36美元的價格購買了207,153股股票。這些交易之後,Cormorant資產管理公司對EyePoint Pharmicals的間接實益所有權共計8,325,000股。本摘要中未提供的腳註詳細說明了間接受益所有權的性質。
Cormorant Asset Management, LP已於2024年5月6日完成了對EyePoint Pharmicals, Inc.(埃及)股份的收購。這些交易在公開市場上執行,共收購了85萬股股票。第一筆交易涉及以每股11.70美元的價格購買642,847股股票,而第二筆交易以每股12.36美元的價格購買了207,153股股票。這些交易之後,Cormorant資產管理公司對EyePoint Pharmicals的間接實益所有權共計8,325,000股。本摘要中未提供的腳註詳細說明了間接受益所有權的性質。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息